The U.S. FDA approved Nuzolvence (zoliflodacin), a single-dose oral treatment for uncomplicated urogenital gonorrhea, based on a non-inferiority Phase 3 trial. Thailand also authorized the drug under the brand Nuzolvance, expanding access in low- and middle-income countries.
DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07730801 |
National Rapid TLC: Testing and Linkage to Care |
NOT_YET_RECRUITING | NA |
| NCT07671014 |
Metagenomic Analysis of the Pharynx in High Risk Partners |
NOT_YET_RECRUITING | |
| NCT07464236 |
Improving Clinic Delivery of HIV-related Anal Health Services |
NOT_YET_RECRUITING | NA |
| NCT06188442 |
Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT04966507 |
Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention |
COMPLETED | PHASE2 |
